Darglitazone

CAS : 141200-24-0

Ref. 3D-RFA20024

Informations sur le produit

• Nom: Darglitazone
• Synonymes: (±)-5-[p-[3-(5-Methyl-2-phenyl-4-oxazolyl)propionyl]benzyl]-2,4-thiazolidinedione, 2,4-Thiazolidinedione, 5-((4-(3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl)phenyl)methyl)-, (+-)-, 5-[[4-[3-(5-Methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]-2,4-thiazolidinedione, 5-{4-[3-(5-Methyl-2-Phenyl-1,3-Oxazol-4-Yl)Propanoyl]Benzyl}-1,3-Thiazolidine-2,4-Dione, Cp 86325, Darglitazone [INN], Unii-Avp9C03Z3K, Darglitazone

Description

Darglitazone is a type of antidiabetic agent that belongs to the thiazolidinedione class. It is used in the treatment of type II diabetes, which is characterized by high blood glucose levels as a result of insulin resistance. Darglitazone has been shown to bind to human fatty acid receptors and activate these receptors, thereby increasing glucose uptake into cells and reducing hepatic glucose production. This drug also has metabolic effects in non-human animals, including an increase in nitrogen-containing compounds such as urea and creatinine. Darglitazone also activates transcription-polymerase chain reaction (PCR) activity on du145 cells in culture. Although the mechanism is not yet fully understood, it may be due to its ability to inhibit protein synthesis or to activate gene expression of proteins involved in the insulin signalling pathway.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 420.5 g/mol
• Formule: C₂₃H₂₀N₂O₄S
• Degré de pureté: Min. 95%